Literature DB >> 26831000

Leukemia Study in Sulaymaniyah Province, Kurdistan, Iraq.

Zhala A A Karim1, Karzan G Khidhir, Rebaz A Ahmed, Halgord A Hassan, Dana Omer Karim.   

Abstract

Entities:  

Mesh:

Year:  2016        PMID: 26831000      PMCID: PMC4799556          DOI: 10.4103/0366-6999.173551

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


× No keyword cloud information.
To the Editor: The increased rate of leukemia in several Iraqi cities has been linked to exposure to depleted uranium, which was used during the consequent wars in Iraq from 1990 to 2010.[1234] Here, we investigated leukemia occurrence in the Sulaymaniyah Governorate (SG), which has been exposed to wars and crises at the same level as the rest of Iraq.[5] To the best of our knowledge, this study is the first population-based study on leukemia in SG. The annual incidence rate for leukemia based on gender, age, and the most common type of leukemia in SG for the period 2009–2013 was calculated from data collected at Hiwa Hospital, which is the only available source of information. Hiwa Hospital had started data collection in 2009, and there were no accurate leukemia data available before. Our study included information about 570 leukemia patients that were registered at Hiwa for treatment. Of these, 367 patients were from SG, which included 176 female and 191 male. The table below summarized the leukemia incidence rate based on gender, age, and type. The statistics indicated that there was higher incidence rate of leukemia among male population (4.1) compared to females (3.6) [Table 1]. In addition, children below age 15 years old have high annual incidence rate (3.4) compared to people aged 15–29 (1.6). Moreover, for >30 years old, an increase trend can be perceived for leukemia in SG [Table 1].
Table 1

Statistics of leukemia occurrence in Sulaymaniyah Governorate for 2009–2013

ParametersnPercentage of cases*Annual rate per 100,000 inhabitants95% CI
Gender
 Female176483.63.14, 4.06
 Male191524.13.59, 4.57
Age (years)
 ≤15110303.42.90, 3.87
 15-2945121.61.14, 2.06
 30-4454152.82.27, 3.33
 45-5956156.03.72, 8.28
 60-74691914.610.48, 18.72
 ≥7533920.214.52, 24.68
Types
 ALL162441.7027.82, 36.58
 CLL69190.0712.13, 15.47
 AML62170.658.54, 16.26
 ML74200.7813.13, 16.47

*Total cases = 367 considered 100%. ALL: Acute lymphoblastic leukemia; CLL: Chronic lymphoblastic leukemia; AML: Acute myeloid leukemia; CML: Chronic myeloid leukemia; CI: Confidence interval.

Statistics of leukemia occurrence in Sulaymaniyah Governorate for 2009–2013 *Total cases = 367 considered 100%. ALL: Acute lymphoblastic leukemia; CLL: Chronic lymphoblastic leukemia; AML: Acute myeloid leukemia; CML: Chronic myeloid leukemia; CI: Confidence interval. Acute Lymphoblastic Leukemia (ALL) is the most common type of leukemia with 44% in all cases and a higher number of cases in patients older than 15 years. In addition, Chronic myeloid leukemia (CML) (20% of all leukemia incidence) is the second highest followed by Chronic lymphoblastic leukemia (CLL, 18%) and Acute myeloid leukemia (AML, 17%) [Table 1]. This is in agreement with the latest international leukemia statistics. However, as shown in Table 1, no cases for CML or CLL and only 7 cases of AML were registered in 5 years. Furthermore, to infer whether exposure to depleted uranium increased the leukemia incidence rate, we analyzed data available for the USA and IARC World standard. The result indicated a lower annual incidence rate of leukemia in SG [Figure 1], suggesting that leukemia in SG has not increased due to war and usage of depleted uranium in Iraq.
Figure 1

Comparison of different types of leukemia at age ≤ 15 years and all ages in SG to USA and IARC World std. ALL: Acute lymphoblastic leukemia; CLL: Chronic lymphoblastic leukemia; AML: Acute myeloid leukemia; CML: Chronic myeloid leukemia; IARC: International Agency for Research on Cancer; SG: Sulaimaniyah Governorate; USA: United States of America; std: Standard.

Comparison of different types of leukemia at age ≤ 15 years and all ages in SG to USA and IARC World std. ALL: Acute lymphoblastic leukemia; CLL: Chronic lymphoblastic leukemia; AML: Acute myeloid leukemia; CML: Chronic myeloid leukemia; IARC: International Agency for Research on Cancer; SG: Sulaimaniyah Governorate; USA: United States of America; std: Standard. Our study is the first population-based study on leukemia and investigates the factors that affect leukemia incidence in Sulaymaniyah province. It also provides information about disease types that can be used as baseline information for further epidemiological studies on leukemia incidence.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  5 in total

1.  Trends in childhood leukemia in Basrah, Iraq, 1993-2007.

Authors:  Amy Hagopian; Riyadh Lafta; Jenan Hassan; Scott Davis; Dana Mirick; Tim Takaro
Journal:  Am J Public Health       Date:  2010-02-18       Impact factor: 9.308

2.  Low birth weight and prematurity in the neonatal unit of a maternity and pediatrics hospital in Iraq.

Authors:  Bushra I Abdul Latif; Jawad K Al-Diwan; Tariq S Al-Hadithi; Abdul Hussein M Al-Hadi
Journal:  J Trop Pediatr       Date:  2005-11-22       Impact factor: 1.165

3.  Depleted uranium: all the questions about DU and Gulf War syndrome are not yet answered.

Authors:  Rosalie Bertell
Journal:  Int J Health Serv       Date:  2006       Impact factor: 1.663

4.  Long-term pulmonary complications of chemical warfare agent exposure in Iraqi Kurdish civilians.

Authors:  Mostafa Ghanei; Mostafa Naderi; Ali Morad Kosar; Ali Amini Harandi; Nicholas S Hopkinson; Zohreh Poursaleh
Journal:  Inhal Toxicol       Date:  2010-08       Impact factor: 2.724

5.  Uranium and other contaminants in hair from the parents of children with congenital anomalies in Fallujah, Iraq.

Authors:  Samira Alaani; Muhammed Tafash; Christopher Busby; Malak Hamdan; Eleonore Blaurock-Busch
Journal:  Confl Health       Date:  2011-09-02       Impact factor: 2.723

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.